Abstract:The gut microbiota influences the effectiveness and side effects of cancer treatments, particularly immunotherapy and associated immune-related complications. This important involvement of the microbiome is supported by the patients receiving antibiotics responding poorly to immunotherapy. Relatively few research has examined the underlying processes, and until recently, data regarding the detection of the microbial organisms that trigger these effects were inconsistent. Since then, a deeper comprehension of the processes of action and taxonomic classification of the relevant species has been attained. It's been demonstrated that certain bacterial species can enhance the body's reaction to immune checkpoint inhibitors through the release of distinct metabolites or products. Nonetheless, in certain patients who are not responding, Gram-negative bacteria may have a dominating suppressive impact. Patients' propensity to react to immunotherapy can be somewhat accurately predicted by machine learning techniques based on their microbiome makeup. Consequently, there has been an increase in interest in modifying the microbiome makeup to enhance patient reaction to medication. Clinical proof-of-concept studies demonstrate that dietary modifications or fecal microbiota transplantation (FMT) might be used therapeutically to increase the efficacy of immunotherapy in cancer patients. Current developments and new approaches for microbiota-based cancer treatments have been emphasized. In conclusion, preclinical research on animals and human clinical trials has made tremendous progress in our understanding of the function of the gut microbiome in health and illness. These investigations have shed light on the effects of food, FMT, probiotics, prebiotics, and microbiome-disease connections. However, there are still a lot of issues and restrictions that must be resolved before this research can be used in real-world clinical settings.

Gut and local microbiota in patients with cancer: increasing evidence and potential clinical applications

The Anti- and Pro-Tumorigenic Role of Microbiota and Its Role in Anticancer Therapeutic Strategies

The gut microbiome and efficacy of cancer immunotherapy

Gut Microbiota Modulation in the Context of Immune-Related Aspects of Lactobacillus spp. and Bifidobacterium spp. in Gastrointestinal Cancers

Role of the Microbiome in the Diagnosis and Management of Gastroesophageal Cancers

Microbiota–Gastric Cancer Interactions and the Potential Influence of Nutritional Therapies

Microbiota and Cancer: The Emerging Beneficial Role of Bifidobacteria in Cancer Immunotherapy

Intestinal Microbiota: A Novel Target to Improve Anti-Tumor Treatment?

Gut microbiota-drug interactions in cancer pharmacotherapies: implications for efficacy and adverse effects

Navigating the complex relationship between human gut microbiota and breast cancer: Physiopathological, prognostic and therapeutic implications

Role of the gut microbiota in anticancer therapy: from molecular mechanisms to clinical applications

Gut Microbiota-Mediated Modulation of Cancer Progression and Therapy Efficacy

Targeting the gut microbiota for cancer therapy

Gut Microbiota–MicroRNA Interactions in Intestinal Homeostasis and Cancer Development

Gut Microbiota-Related Biomarkers in Immuno-Oncology

Role of the Microbiota in Lung Cancer: Insights on Prevention and Treatment

Role of Gut Microbiome in Cancer Treatment

The Emerging Role of the Microbiota in Breast Cancer Progression

Gastric Cancer, Immunotherapy, and Nutrition: The Role of Microbiota

Interaction of the Gut Microbiome With Cancer Treatment

The role of gut microbiota in cancer treatment: friend or foe?